06/03/2021 11:45 am Welcome to isteroids.com - BLOG

Tuesday 22, Jun 2010

  Drug combination effective to treat patients with multiple myeloma

Posted By
Pin it Share on Tumblr

Drug combination effective to treat patients with multiple myelomaDuring a study conducted at 44 centers in the United States and Canada and involving 353 patients with myeloma, it was found that a combination of drugs lenalidomide and dexamethasone could be useful for treating patients.

It was found during the study that pairing a new derivative of thalidomide with a steroid could slow down the progress of multiple myeloma along with prolonging lives of patients who have earlier relapsed from past treatments.

It was remarked by lead author Donna Weber, M.D., associate professor in the Department of Lymphoma and Myeloma at the University of Texas M. D. Anderson Cancer Center that these combinational drugs are effective as the disease may become immune to one therapy.

Tuesday 16, Feb 2010

  Lenalidomide and Dexamethasone combination useful for treating multiple myeloma patients

Posted By
Pin it Share on Tumblr

Lenalidomide and Dexamethasone combination useful for treating multiple myeloma patientsMultiple myeloma can be effectively treated by using a combination of lenalidomide and dexamethasone, according to a study that involved 353 patients with myeloma and conducted at 44 centers in the United States and Canada.

It was revealed during the study that pairing a new thalidomide derivative with a steroid can slow down the progression of multiple myeloma besides prolonging the lives of patients who have relapsed from earlier treatments.

Lead author Donna Weber, M.D., associate professor in the Department of Lymphoma and Myeloma at The University of Texas M. D. Anderson Cancer Center, said that the combination seems to be effective as the disease may become immune to one therapy.

Wednesday 02, Sep 2009

  Lenalidomide and dexamethasone effectual against multiple myeloma

Posted By
Pin it Share on Tumblr

Lenalidomide and dexamethasone effectual against multiple myeloma The combination of lenalidomide and dexamethasone is effectual against multiple myeloma: this was a fact that was revealed after a study involving 353 patients with myeloma was conducted at 44 centers in the United States and Canada.

The study also found out that pairing a new thalidomide derivative with a steroid can considerably slowdown any further progression of multiple myeloma, which is an incurable bone marrow cancer. It was also revealed that this combination may also prove its worth to prolong lives of patients who have relapsed from previous treatments.

It was remarked by lead author Donna Weber, M.D., Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas M. D. Anderson Cancer Center that a combination of medical drugs may prove to be beneficial in ongoing treatment as a disease may become resistant to one drug.

Tuesday 18, Aug 2009

  Combination of dexamethasone, Velcade, and lenalidomide effective for multiple myeloma

Posted By
Pin it Share on Tumblr

Combination of dexamethasone, Velcade, and lenalidomide effective for multiple myelomaAccording to a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology, a new combo of Velcade with dexamethasone and lenalidomide can prove to be effective for patients who have been recently diagnosed with multiple myeloma.

The combination of these three drugs is effective for treating multiple myeloma patients who have relapsed after failing to respond to standard treatment therapies or after successful treatment.

From News-Medical.Net:

The three-pronged regimen of Velcade, lenalidomide (Revlimid) and dexamethasone – referred to as Rev/Vel/Dex – has achieved an overall response rate of 98 percent in 42 patients evaluated thus far in a Phase 1-2 trial, said Paul Richardson, MD, of Dana-Farber and the study’s principal investigator. He added that 52 percent of the patients had high quality responses (very good partial response or better), with 30 percent achieving complete response to date.

“These may be some of the best response rates we’ve seen to date with up-front therapies, and although these are preliminary results, they are extremely promising,” Richardson said. The patients were previously untreated when they received the Rev/Vel/Dex combination.

Velcade is a “smart” drug known as a proteasome inhibitor that blocks the myeloma cells’ waste disposal system, creating an accumulation of toxic compounds that poison the cell. Revlimid is a chemical relative of thalidomide that affects several pathways in cancer cells, including immune mechanisms and blood vessel growth to tumors. Dexamethasone is a steroid hormone that counters inflammation and is used to treat hematologic malignancies such as myeloma. Studies leading to the trial of the three drugs in combination were carried out at Dana-Farber.

The findings are expected to offer much-awaited relief to patients with multiple myeloma, who have been expecting an effective treatment methodology for the last many years.